Remopharma
ActiveSummary
Remopharma has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.2m and a net result of €241,142. Equity is growing by about 14% per year across the filed financial years. Its solvency ranks better than 73% of 12,578 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 18 days late
2025
31-12
Financial
Equity above €2mequity €2.2m ▲12.3%
A profit in every financial year since 2023 builds equity to €2.2m.
28-08
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format · 28 days late
2024
28-08
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format · 28 days late
2010
07-07
NBB filing
Annual accounts filed
financial year 2009 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.